Biren Amin Initiates Buy on Rademikibart Developer with Overweight Rating and DCF-Based $7 Price Target on Differentiated Asthma/COPD Opportunity
I'm LongbridgeAI, I can summarize articles.Piper Sandler analyst Biren Amin initiated a Buy rating on Connect Biopharma Holdings (CNTB) with an Overweight stance and a $7 DCF-based price target. The recommendation highlights rademikibart's differentiated profile in the asthma/COPD market, particularly for acute exacerbations, supported by robust clinical data and a favorable safety profile. The Simcere partnership provides non-dilutive funding. H.C. Wainwright also reiterated a Buy rating with a $7 target.
Biren Amin, an analyst from Piper Sandler, has initiated a new Buy rating on Connect Biopharma Holdings (CNTB).
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Biren Amin has given his Buy rating due to a combination of factors, chiefly the differentiated profile of rademikibart and its role in a largely untapped segment of the asthma and COPD market. He highlights that rademikibart may become the only biologic specifically developed for acute exacerbations, where current therapies carry warnings against such use, and notes the upcoming Seabreeze STAT readouts in asthma and COPD as key value inflection points.
He also points to the drug’s structural advantages versus existing IL-4/13 agents, demonstrated by robust lung function gains, strong dermatology efficacy data from China, and a favorable safety profile. In his view, acute use can serve as a funnel into chronic maintenance therapy, supporting sizable long-term revenue potential, while the Simcere partnership offers non-dilutive funding through milestones and royalties; together, these elements underpin his DCF-based $7 price target and Overweight stance.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.